A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population

References

• 1 Leucht S, Cipriani A, Spineli L. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896), 951–962(2013).
  Medline CASGoogle Scholar
• 2 Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad. Med. 120(2), 18–33(2008).
  MedlineGoogle Scholar
• 3 Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150(6), 1115–1121(2005).
  MedlineGoogle Scholar
• 4 Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch. Gen. Psychiatry 64(2), 242–249(2007).
  MedlineGoogle Scholar
• 5 Wong MM, Chen EY, Lui SS, Tso S. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin. Schizophr. Relat. Psychoses 5(3), 135–141(2011).
  MedlineGoogle Scholar
• 6 Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17(3), 242–266(2012).
  Medline CASGoogle Scholar
• 7 Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol. Ther. 125(1), 169–179(2010).
  Medline CASGoogle Scholar
• 8 Risselada AJ, Mulder H, Heerdink ER, Egberts TC. Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics 12(8), 1213–1227(2011).
  CASGoogle Scholar
• 9 Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7(6), 863–887(2006).
  CASGoogle Scholar
• 10 Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr. Genet. 12(1), 55–58(2002).
  MedlineGoogle Scholar
• 11 Lane HY, Liu YC, Huang CL. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 26(2), 128–134(2006).
  Medline CASGoogle Scholar
• 12 Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J. 11(1), 35–44(2011).
  Medline CASGoogle Scholar
• 13 Lencz T, Robinson DG, Napolitano B. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet. Genomics 20(9), 569–572(2010).
  Medline CASGoogle Scholar
• 14 Liu YR, Loh EW, Lan TH. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J. 10(1), 30–39(2010).
  Medline CASGoogle Scholar
• 15 Sickert L, Muller DJ, Tiwari AK. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 10(7), 1169–1176(2009).
  CASGoogle Scholar
• 16 Vehof J, Risselada AJ, Al Hadithy AF. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl.) 216(2), 257–265(2011).
  Medline CASGoogle Scholar
• 17 Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 1021–1028(2005).
  Medline CASGoogle Scholar
• 18 Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller DD. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull. 40(1), 57–62(2007).
  MedlineGoogle Scholar
• 19 Purcell S, Neale B, Todd-Brown K. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559–575(2007).
  Medline CASGoogle Scholar
• 20 Tiwari AK, Zai CC, Likhodi O. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 35(6), 1315–1324(2010).
  Medline CASGoogle Scholar
• 21 Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 29(4), 1165–1188(2001).
  Google Scholar
• 22 Lieberman JA, Stroup TS, Mcevoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223(2005).
  Medline CASGoogle Scholar
• 23 Tecott LH, Sun LM, Akana SF. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374(6522), 542–546(1995).
  Medline CASGoogle Scholar
• 24 Dourish CT, Hutson PH, Curzon G. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology (Berl.) 86(1–2), 197–204(1985).
  Medline CASGoogle Scholar
• 25 Clifton PG, Lee MD, Dourish CT. Similarities in the action of Ro 60–0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berl.) 152(3), 256–267(2000).
  Medline CASGoogle Scholar
• 26 Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 29(1), 65–68(2009).
  Medline CASGoogle Scholar
• 27 De Luca V, Mueller DJ, De Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol. 10(5), 697–704(2007).
  Medline CASGoogle Scholar
• 28 Sicard MN, Zai CC, Tiwari AK. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11(11), 1561–1571(2010).
  CASGoogle Scholar
• 29 Sookoian S, Gianotti TF, Gemma C, Burgueno A, Pirola CJ. Contribution of the functional 5-HTTLPR variant of the SLC6A4 gene to obesity risk in male adults. Obesity 16(2), 488–491(2008).
  Medline CASGoogle Scholar
• 30 Giannaccini G, Betti L, Palego L. The expression of platelet serotonin transporter (SERT) in human obesity. BMC Neurosci. 14, 128(2013).
  MedlineGoogle Scholar
• 31 Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11(3), 265–268(2001).
  Medline CASGoogle Scholar
• 32 Bozina N, Medved V, Kuzman MR, Sain I, Sertic J. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J. Psychopharmacol. 21(7), 728–734(2007).
  Medline CASGoogle Scholar
• 33 Liu C, Zhang F, Li T. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics 13, 661(2012).
  Medline CASGoogle Scholar
• 34 Malhotra AK, Correll CU, Chowdhury NI. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 69(9), 904–912(2012).
  Medline CASGoogle Scholar
• 35 Adkins DE, Aberg K, Mcclay JL. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 16(3), 321–332(2011).
  Medline CASGoogle Scholar